LUMINESCENT COMPOUNDS
20210005824 ยท 2021-01-07
Inventors
- Alex ROBINSON (Birmingham, West Midlands, GB)
- Jon PREECE (Birmingham, West Midlands, GB)
- Gregory O'CALLAGHAN (Birmingham, West Midlands, GB)
- Karolis VIRZBICKAS (Birmingham, West Midlands, GB)
- Owen JONES (Birmingham, West Midlands, GB)
- Dennis ZHAO (Birmingham, West Midlands, GB)
- Michael BUTLIN (Birmingham, West Midlands, GB)
- Sareena SUND (Birmingham, West Midlands, GB)
Cpc classification
H10K50/125
ELECTRICITY
C07D413/04
CHEMISTRY; METALLURGY
H10K85/6574
ELECTRICITY
C07D409/04
CHEMISTRY; METALLURGY
C07C217/94
CHEMISTRY; METALLURGY
C07D263/52
CHEMISTRY; METALLURGY
H10K85/615
ELECTRICITY
Y02E10/549
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
International classification
C07D263/52
CHEMISTRY; METALLURGY
C07D409/04
CHEMISTRY; METALLURGY
Abstract
Polycyclic aromatic hydrocarbon derivatives represented by the following general formula: (I) wherein R independently represents an aromatic group and/or an aliphatic group; Q is one of a cyclic aliphatic hydrocarbon, a cyclic aromatic hydrocarbon, a polycyclic hydrocarbon, a polycyclic aromatic hydrocarbon, and/or a fused polycyclic aromatic hydrocarbon; wherein the substituents independently comprise one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom (e.g. an alkylated oxygen atom), a nitrogen atom (e.g. an alkylated nitrogen atom), a cyano group, a nitro group, an alkyl group and/or an aryl group; p is an integer of 1 to 2; q is an integer of 1 to 4; Y.sup.1 and Y.sup.2 independently represent one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom (e.g. an alkylated oxygen atom), a nitrogen atom (e.g. an alkylated nitrogen atom), a cyano group, a nitro group, an alkyl group and/or an aryl group; and x is an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
##STR00001##
Claims
1-39. (canceled)
40. Polycyclic aromatic hydrocarbon derivatives represented by the following general formula: ##STR00024## wherein R independently represents an aromatic group and/or an aliphatic group; Q is one of a cyclic aliphatic hydrocarbon, a cyclic aromatic hydrocarbon, a polycyclic hydrocarbon, a polycyclic aromatic hydrocarbon, and/or a fused polycyclic aromatic hydrocarbon; wherein the substituents independently comprise one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group; p is an integer of 1 to 2; q is an integer of 1 to 4; Y.sup.1 and Y.sup.2 independently represent one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group; and x is an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more.
41. Polycyclic aromatic hydrocarbon derivatives according to claim 40, wherein Q is an aromatic six-membered ring, and x an integer of 2 or more.
42. Polycyclic aromatic hydrocarbon derivatives according to claim 40, represented by the following general formula: ##STR00025## wherein R independently represents an aromatic group and/or an aliphatic group; p is an integer of 1 to 2; q and s are independently integers of 1 to 4; Y.sup.1, Y.sup.2, and Y.sup.3 independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group.
43. Polycyclic aromatic hydrocarbon derivatives according to claim 42, represented by the following general formula: ##STR00026## wherein R independently represents an aromatic group and/or an aliphatic group; q is independently an integer of 1 to 3; s is independently an integer of 1 to 4; t is independently an integer of 1 to 4; Y.sup.2, Y.sup.3, and Y.sup.4 and J independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group.
44. Polycyclic aromatic hydrocarbon derivatives according to claim 42, wherein the polycyclic aromatic hydrocarbon derivatives are triphenylene derivatives represented by the following general formula: ##STR00027## wherein R independently represents an aromatic group and/or an aliphatic group; A independently represents a hydrogen atom, an aryl group, an alkyl group comprising 1 to 20 carbons or an alkyl ether; J independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group.
45. Polycyclic aromatic hydrocarbon derivative according to claim 40, represented by the following general formula: ##STR00028## wherein R.sup.1 and R.sup.2 independently represents an aromatic group and/or an aliphatic group; p and q are independently an integer of 1 to 2; s is an integer of 1 to 4; Y.sup.1, Y.sup.2, and Y.sup.3 independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group.
46. Polycyclic aromatic hydrocarbon derivative according to claim 40, represented by the following general formula: ##STR00029## wherein R.sup.1, R.sup.2, R.sup.3 independently represent an aromatic group and/or an aliphatic group; p, q, and s are each independently an integer of 1 to 2; Y.sup.1, Y.sup.2, and Y.sup.3 independently represent a hydrogen atom, d a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group.
47. Polycyclic aromatic hydrocarbon derivative according to claim 42, wherein R is an alkyl group.
48. Polycyclic aromatic hydrocarbon derivative according to claim 42, wherein R is an aromatic group.
49. Polycyclic aromatic hydrocarbon derivative according to claim 48, wherein R is a heterocyclic aromatic group.
50. The polycyclic aromatic hydrocarbon derivatives according to claim 48, wherein R is a polycyclic aromatic hydrocarbon.
51. The polycyclic aromatic hydrocarbon derivatives according to claim 42 selected from the structures shown in
52. A device comprising a polycyclic aromatic hydrocarbon according to claim 40.
53. A device according to claim 52, wherein the device is an organic electroluminescent device, an OPV (organic photovoltaic) device, a thin-film transistor, or a liquid crystal display.
54. A device according to claim 52, wherein the polycyclic aromatic hydrocarbon derivatives exhibit a Stokes shift of between 200 cm.sup.1 to 36,000 cm.sup.1.
55. A method of synthesising polycyclic aromatic hydrocarbon derivatives, the method comprising the general formula: ##STR00030## wherein (SM2) represents the polycyclic aromatic hydrocarbon core, (P2) represents the polycyclic aromatic hydrocarbon derivative; Q is one of a substituted or unsubstituted cyclic aliphatic hydrocarbon, a substituted or unsubstituted cyclic aromatic hydrocarbon, a substituted or unsubstituted polycyclic hydrocarbon, a substituted or unsubstituted polycyclic aromatic hydrocarbon, and/or a substituted or unsubstituted fused polycyclic aromatic hydrocarbon; wherein the substituents comprise one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group; p is an integer of 1 to 2; q is an integer of 1 to 4; Y.sup.1 and Y.sup.2 independently represent one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group; and x is an integer of 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more; G is a carbon atom; N is a nitrogen atom; B is one or more hydrogen atoms; and wherein (E) represents a reagent; R independently represents an aromatic group and/or an aliphatic group; Z is one of an oxygen atom, a derivatised oxygen atom, a chlorine atom, or a bromine atom, or any good leaving group.
56. A method of synthesising polycyclic aromatic hydrocarbon derivatives according to
55. and the following general formula: ##STR00031## wherein (SM3) represents the polycyclic aromatic hydrocarbon core, (P3) represents the polycyclic aromatic hydrocarbon derivative, p is an integer of 1 to 2; q and s are integers of 1 to 4; Y.sup.1, Y.sup.2, and Y.sup.3 independently represent one or more of a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group; G is a carbon atom; N is a nitrogen atom; B is one or more hydrogen atoms; (E) represents the reagent; R independently represents an aromatic group and/or an aliphatic group ; Z is one of an oxygen atom, a derivatised oxygen atom, a chlorine atom, or a bromine atom, or any good leaving group; and wherein the polycyclic aromatic hydrocarbon core (SM3) and the reagent (E) undergo an intermolecular coupling reaction to produce the polycyclic aromatic hydrocarbon derivative (P3).
57. A method of synthesising triphenylene derivatives according to claim 56, and the following general formula: ##STR00032## wherein (SM4) represents a triphenylene core, (P4) represents a triphenylene derivative; A independently represents a hydrogen atom, an aryl group, an alkyl group comprising 1 to 20 carbons; J independently represent a hydrogen atom, a deuterium atom, a fluorine atom, a chlorine atom, a bromine atom, a carbon atom, an oxygen atom, a nitrogen atom, a cyano group, a nitro group, an alkyl group and/or an aryl group. G is a carbon atom; (E) represents the reagent; R independently represents an aromatic group and/or an aliphatic group; Z is one of an oxygen atom, a derivatised oxygen atom, a chlorine atom, or a bromine atom, or any good leaving group; and wherein the triphenylene core (SM4) and the reagent (E) undergo an intermolecular coupling reaction to produce the triphenylene derivative (P4)
58. A method according to claim 55, further comprising a catalyst.
59. A method according to claim 58, wherein the catalyst is a transition metal catalyst.
Description
[0197] Embodiments of the invention will now be described by way of example only with reference to the accompanying drawings in which:
[0198]
[0199]
[0200]
[0201]
[0202]
[0203]
[0204]
[0205]
[0206]
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215] Referring now to
[0216] Referring now to
[0217] Without wishing to be bound by theory, it is thought that the reaction Precursor 1 in Pathway A proceeds via an intramolecular ring closure mechanism to lead to the formation of Compound 1 in quantitative yield. The carbazole 301 product was not observed. The method of synthesising Compound 1 is described in Example 1 below. It should be noted that Compound 1 is synthesised using the intramolecular route. We have found that other alkyl analogues (e.g. C7, C8 analogues) can be made in a similar fashion. Other embodiments of the invention require a different method of synthesis, which proceeds via a different chemical mechanism.
[0218] Referring now to
[0219] Referring now to
[0220] The following general procedure may be followed to synthesise the triphenylene derivative series 100 using the method 500A of
[0221] This method was based on a prior art method for the formation of a carbazole (J. A. Jordan-Hore, C. C. C. Johansson, M. Gulias, E. M. Beck, M. J. Gaunt, J. Am. Chem. Soc., 2008, 130, 16184-16186.) and, as previously stated, was surprisingly able to form the triphenyl derivative series 100, i.e. the triphenylene oxazole.
[0222] Referring also to
[0223] The following general procedure may be followed to synthesise the triphenylene derivative series 100 using the method 500B of
[0224] Without wishing to be bound by theory, the inventors believe that the acyl chloride 502 forms an intermediate amide (shown in
[0225] Advantageously, the methods of
[0226] Referring now to
[0227] To further exemplify the invention, reference is also made to the following non-limiting Examples.
[0228] All compound names were generated using ChemDraw software.
[0229] Referring to
EXAMPLE 1METHOD OF SYNTHESISING COMPOUND 1
[0230] Compound 1 was synthesised using the following method. A solution of Precursor 1 (100 mg; 0.13 mmol) in o-xylene (8 mL) was added to a flask. This was then heated and held at 175 C. for 16 h to afford Compound 1 (51% yield).
[0231] In the alternative, Compound 1 was synthesised using the following method. A solution of Precursor 1 (100 mg; 0.13 mmol) in dry PhMe (8 mL) was added to a flask containing rhodium octanoate dimer (8 mg; 0.01 mmol), under a N.sub.2 atmosphere. This was then heated and held at reflux for 20 h. The reaction was cooled to room temperature and then evaporated to dryness in vacuo, the solid was then purified via flash column chromatography (silica; 95% n-hexane:5% ethyl acetate) to afford Compound 1 as a white solid (96 mg; 99%).
[0232] The name for Compound 1 is 8-butyl-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0233] Compound 1 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.01 (1 H, s), 7.94 (1 H, s), 7.90 (1 H, s), 7.88 (1 H, s), 7.85 (1 H, s), 4.42 (2 H, t, J 6.7 Hz), 4.37 (2H, t, J 6.7 Hz) 4.29-4.23 (6 H, m), 3.09 (2 H, t, J 7.5 Hz), 2.05-1.92 (10 H, m), 1.62-1.43 (24 H, m), 1.06-0.96 (18 H, m) ppm. .sup.13C NMR (100 MHz, CDCl3) C: 165.6, 149.5, 149.1, 148.7, 148.3, 142.9, 140.1, 139.8, 124.6, 123.9, 123.5, 123.3, 116.3, 111.0, 108.3, 106.9, 106.8, 102.6, 69.9, 69.6, 69.5, 68.8, 29.2, 29.0, 28.8, 28.4, 28.3, 22.6, 22.4, 14.2, 13.9 ppm. ES+ MS m/z: 756.5 ([M+H].sup.+ 15%), 778.5 ([M.sup.+ Na].sup.+ 100%). IR .sup.1 (neat): 3112 w (CH), 2953 m (CH), 1617 w (CN), 1517 w (benzene ring), 1259 s (CO), 1177 s (CO), 1159 s (CO) cm1. Elemental analysis Found: C, 76.09; H, 9.17; N, 1.95. C.sub.48H.sub.69NO.sub.6 requires C, 76.25; H, 9.20; N, 1.85%.
EXAMPLE 2METHOD OF SYNTHESISING COMPOUND 2
[0234] Compound 2 was synthesised using the following method. A slurry of benzoic acid (160 mg; 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.16 mmol) in PhMe (5 mL) was heated at 70 C. under N.sub.2 for 20 min. Precursor 2 (100 mg, 0.13 mmol) in PhMe (2 mL) was added and the reaction was heated and held at reflux for 72 h. The mixture was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The mixture was washed with 1M NaOH (220 mL) and the organic phase was dried in vacuo. The crude black solid was purified via flash column chromatography (60% n-hexane: 40% CH.sub.2Cl.sub.2) to afford Compound 2 as a white solid (35 mg; 34%).
[0235] The name for Compound 2 is 2,3,6,11,12-pentakis(pentyloxy)-8-phenyltriphenyleno[1,2-d]oxazole.
[0236] Compound 2 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.13 (1H, s), 8.40-8.37 (2H, m), 7.92 (1H, s), 7.88 (1H, s), 7.87 (1H, s), 7.77 (1H, s), 7.57-7.55 (1H, m), 4.48-4.43 (4H, m), 4.30-4.23 (6H, m), 2.12-1.92 (10H, m), 1.69-1.54 (12H, m), 1.53-1.45 (12H, m), 1.04-0.96 (18H, m) ppm. .sup.13C NMR (100 MHz, CDCl.sub.3) C: 161.4, 149.5, 149.0, 148.7, 148.3, 142.9, 140.5, 140.2, 131.2, 128.9, 127.5, 127.1, 124.7, 123.8, 123.4, 123.3, 116.4, 110.9, 108.2, 106.8, 106.6, 103.8, 69.8, 69.5, 68.9, 29.2, 29.0, 28.4, 28.3, 22.6, 22.6, 14.1 ppm. ES+MS m/z: 775.5 ([M]+ 22%), 776.5 ([M+H]+ 37%), 798.5 ([M+Na]+ 100%). Elemental analysis Found: C, 77.46; H, 8.44; N, 1.75%. C.sub.50H.sub.65NO.sub.6 requires C, 77.38; H, 8.44; N, 1.80%.
EXAMPLE 3METHOD OF SYNTHESISING COMPOUND 3
[0237] Compound 3 was synthesised using the following method. A solution of 2-naphthalene carboxylic acid (225 mg, 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in PhMe (5 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg; 0.131 mmol) in PhMe (2 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 3 as a yellow solid (35 mg; 32%).
[0238] The name for Compound 3 is 8-(naphthalen-2-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0239] Compound 3 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.22 (1H, s), 8.89 (1H, s), 8.49 (1H, dd, J 8.6, 1.7), 8.05-7.99 (2H, m), 7.96-7.91 (5 H, m), 7.62-7.59 (2H, m), 4.54 (2H, t, J 6.8), 4.51 (2H, t, J 6.8), 4.32-4.25 (6H, m), 2.17-1.93 (10H, m), 1.76-1.42 (20H, m), 1.06-0.97 (15H, m) ppm. .sup.13C NMR (100 MHz, CDCl.sub.3) C: 161.7, 149.8, 149.3, 149.0, 148.6, 143.2, 140.9, 140.6, 135.0, 133.4, 129.3, 128.9, 128.3, 128.0, 127.9, 127.4, 127.2, 125.0, 125.0, 124.4, 124.2, 123.7, 123.6, 116.7, 111.2, 108.5, 107.1, 107.0, 103.9, 70.2, 70.1, 69.8, 69.2, 29.6, 29.5, 28.9, 28.8, 28.7, 23.1, 23.0, 14.6, 14.5 ppm. MALDI+ m/z: 825.5 ([M]+ 100%). IR 1 (neat): Elemental analysis Found: C, 78.95; H, 8.02; N, 1.83%. C.sub.54H.sub.67NO.sub.6 requires C, 78.51; H, 8.17; N, 1.70%.
EXAMPLE 4METHOD OF SYNTHESISING COMPOUND 4
[0240] Compound 4 was synthesised using the following method. A solution of 1-naphthalene carboxylic acid (225 mg, 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in PhMe (5 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100mg; 0.131 mmol) in PhMe (2 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 4 as a yellow solid (24 mg; 22%).
[0241] The name for Compound 4 is 8-(naphthalen-1-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0242] Compound 4 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.15 (1H, s), 9.82 (1H, d, J 8.3 Hz), 8.59 (1H, dd, J 7.3, 1.2 Hz), 8.08 (1H, d, J 8.3 Hz), 8.01-7.98 (3H, m), 7.94 (2H, m), 7.71-7.61 (3H, m), 4.54-4.45 (4H, m), 4.32-4.26 (6H, m), 2.10-1.94 (10H, m), 1.70-1.35(20H, m), 1.04-0.87 (15H, m) ppm. .sup.13C NMR (100 MHz, CDCl.sub.3) C: 161.3, 149.9, 149.6, 149.1, 148.8, 143.2, 141.0, 139.9, 134.5, 132.4, 131.0, 129.6, 129.2, 127.8, 127.5, 126.9, 126.7, 125.5, 125.0, 124.2, 124.1, 123.8, 117.0, 111.0, 108.6, 107.3, 107.2, 104.4, 70.2, 69.9, 69.1, 29.6, 29.5, 29.0, 28.8, 28.7, 23.0, 14.5 ppm. MALDI+ m/z: 826.7 ([M+H]+ 100%). Elemental analysis Found: C, 78.49; H, 8.23; N, 1.73%. C.sub.54H.sub.67NO.sub.6 requires C, 78.51; H, 8.17; N, 1.70%.
EXAMPLE 5METHOD OF SYNTHESISING COMPOUND 5
[0243] Compound 5 was synthesised using the following method. A solution of 2-anthracene carboxylic acid (290 mg, 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in PhMe (5 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg; 0.131 mmol) in PhMe (2 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 5 as a yellow solid (22 mg; 20%).
[0244] The name for Compound 5 is 8-(anthracen-2-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0245] Compound 5 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.20 (1H, s), 9.00 (1H, s), 8.58 (1H, s), 8.47 (1H, s), 8.39 (1H, dd, J 8.9, 1.6 Hz) 8.13-8.10 (2H, m), 8.07-8.02 (2H, m), 7.93 (1H, s), 7.90-7.89 (3H, m), 4.57-4.47 (4H, m), 4.31-4.24 (6H, m), 2.19-1.96 (10H, m), 1.76-1.44 (20H, m), 1.08-0.97 (15H, m) ppm. .sup.13C NMR (100 MHz, CDCl.sub.3) C: 161.8, 149.8, 149.4, 149.0, 148.6, 143.2, 141.0, 140.6, 133.1, 132.6, 132.3, 131.2, 129.2, 128.7 128.6, 128.2 127.4, 126.8, 126.6, 126.3, 125.0, 124.4, 124.2, 123.8, 123.6, 116.7, 111.3, 108.5, 107.1, 107.0, 104.0, 70.2, 70.1, 69.8, 69.2, 30.1, 29.6, 29.5, 28.9, 28.8, 28.7, 23.1, 23.0, 14.7, 14.5 ppm. MALDI+ m/z: 876.5 ([M+H]+ 100%). Elemental analysis Found: C, 79.49; H, 7.88; N, 1.51. C.sub.58H.sub.69NO.sub.6 requires C, 79.51; H, 7.94; N, 1.60%.
EXAMPLE 6METHOD OF SYNTHESISING COMPOUND 6
[0246] Compound 6 was synthesised using the following method. A solution of 9-anthracene carboxylic acid (290 mg; 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in o-xylene (5 mL) was heated to 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg, 0.131 mmol) in o-xylene (2 mL) was added and heated to 140 C. for 72 h. The mixture was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The mixture was washed with 1M NaOH (220 mL) and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 6 as a yellow solid (13 mg; 11%).
[0247] The name for Compound 6 is 8-(anthracen-9-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0248] Compound 6 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.18 (1H, s), 8.70 (1H, s), 8.49-8.44 (2H, m), 8.15-8.09 (2 H, m), 8.03 (1H, s) 8.02 (1H, s) 7.95 (1H, s), 7.94 (1 H,$) 7.58-7.52 (4 H, m), 4.50 (2 H, t, J 6.7 Hz), 4.33-4.27 (6 H, m), 4.17 (2 H, t, J 6.7 Hz), 2.05-1.93 (8H, m), 1.79 (2H, p, J 6.7, 1.0 Hz) 1.66-1.37 (20H, m), 1.03 -0.92 (15 H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 160.6, 150.0, 149.6, 149.2, 148.8, 143.5, 141.0, 140.7, 131.9, 131.7, 131.3, 129.1, 127.7, 127.6, 126.4, 125.9 124.2, 123.8, 121.1, 117.1, 111.3, 108.7, 107.3, 107.2, 104.6, 70.4, 70.3, 69.9, 69.2, 29.6, 29.5, 29.0, 28.8, 28.7, 28.6, 28.5, 23.0, 22.9, 22.6, 14.5, 14.4, 14.3 ppm. MALDI.sup.+ m/z: 876.5 ([M+H].sup.+ 100%). Elemental analysis Found: C, 79.13; H, 7.83; N, 1.77%. C.sub.58H.sub.69NO.sub.6 requires C, 79.51; H, 7.94; N, 1.60%.
EXAMPLE 7METHOD OF SYNTHESISING COMPOUND 7
[0249] Compound 7 was synthesised using the following method. A solution of 4-fluorobenzoic acid (187 mg; 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in o-xylene (5 mL) was heated to 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg, 0.131 mmol) in o-xylene (2 mL) was added and heated to 140 C. for 72 h. The mixture was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The mixture was washed with 1M NaOH (220 mL) and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 7 as a yellow solid (13 mg; 9%).
[0250] The name for Compound 7 is 8-(4-fluorophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0251] Compound 7 had the following characterisation data: .sup.1H NMR (300 MHz; CDCl.sub.3) H: 10.03 (s, 1H), 8.36-8.30 (m, 2H), 7.97-7.75 (m, 4H), 7.28-7.15 (m, 3H), 4.41 (t, J=6.6 Hz, 4H), 4.26 (m, 6H), 2.06-1.90 (m, 9H), 1.55 (m, 22H), 1.05-0.95 (m, 15H) ppm. .sup.13C NMR (100 MHz; CDCl.sub.3) C: 166.0, 163.5, 160.6, 149.7, 149.1, 148.9, 148.5, 143.0, 140.5, 140.3, 129.8, 129.7, 127.3, 124.8, 123.9, 123.8, 123.5, 116.5, 116.3, 116.1, 111.1, 108.4, 107.0, 106.8, 103.7, 69.9, 69.8, 69.7, 69.5, 68.9, 29.7, 29.2, 29.0, 28.5, 28.4, 28.3, 22.6, 14.2, 14.1 ppm. .sup.19F NMR (282 MHz, CDCl.sub.3) F: 108.0 ppm. MALDI+ m/z: 795.6 ([M+H+1].sup.+ 15%), 794.6 ([M+H].sup.+ 55%), 793.6 ([M]+ 100%). IR .sup.1 (neat): 2952 m (CH), 2926 m (CH), 2858 m (CH), 1616 w (CN), 1517 s (benzene ring), 1499 m (benzene ring), 1433 m (benzene ring), 1261 m (CO), 1174 s (CO) cm.sup.1.
EXAMPLE 8METHOD OF SYNTHESISING COMPOUND 8
[0252] Compound 8 was synthesised using the following method. A solution of 3-fluorobenzoic acid (182 mg; 1.30 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in o-xylene (5 mL) was heated to 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg, 0.131 mmol) in o-xylene (2 mL) was added and heated to 140 C. for 72 h. The mixture was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The mixture was washed with 1M NaOH (220 mL) and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 8 as a yellow solid (13 mg; 11%).
[0253] The name for Compound 8 is 8-(3-fluorophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0254] Compound 8 had the following characterisation data: .sup.1H NMR (300 MHz; CDCl.sub.3) H: 10.06 (s, 1H), 8.15 (d, J=7.9 Hz, 1H), 8.05 (dd, J=9.0, 1.9 Hz, 1H), 7.89 (m, 4H), 7.53 (m, 1H), 7.36-7.16 (m, 4H), 4.45 (m, 4H), 4.33-4.21 (m, 6H), 2.16-1.90 (m, 11H), 1.71-1.39 (m, 24H), 1.06-0.93 (m, 15H) ppm. .sup.13C NMR (100 MHz; CDCl.sub.3) C: 164.3, 161.8, 160.1, 160.1, 149.6, 149.1, 148.8, 148.4, 142.9, 140.3, 140.3, 130.6, 130.5, 129.6, 129.6, 127.3, 124.8, 123.7, 123.4, 123.4, 123.2, 123.2, 118.3, 118.1, 116.4, 114.6, 114.3, 110.9, 108.2, 106.8, 106.7, 103.9, 69.9, 69.8, 69.6, 69.0, 29.4, 29.3, 29.2, 28.6, 28.5, 28.4, 22.8, 14.3 ppm. 19F NMR (282 MHz; CDCl3) F: 111.8 ppm. ES+MS m/z: 817.5 ([M+H.sup.+Na].sup.+ 50%), 816.5 ([M+Na].sup.+ 100%), 794.5 ([M]+ 55%). IR 1 (neat): 2952 m (CH), 2925 m (CH), 2856 m (CH), 1617 w (CN), 1518 s (benzene ring), 1434 s (benzene ring), 1262 s (CO), 1174 s (CO) cm1. Elemental analysis Found: C, 75.62; H, 8.25; N, 1.78%. C.sub.50H.sub.64FNO.sub.6 requires C, 75.63; H, 8.12; N, 1.76%.
EXAMPLE 9METHOD OF SYNTHESISING COMPOUND 9
[0255] Compound 9 was synthesised using the following method. A solution of 2-fluorobenzoic acid (41.86 mg; 0.26 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in o-xylene (5 mL) was heated to 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg, 0.131 mmol) in o-xylene (2 mL) was added and heated to 140 C. for 72 h. The mixture was cooled to room temperature and diluted with CH2C12 (20 mL). The mixture was washed with 1M NaOH (220 mL) and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 9 as a yellow solid (7 mg; 10%).
[0256] The name for Compound 9 is 8-(2-fluorophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0257] Compound 9 had the following characterisation data: .sup.1H NMR (300 MHz; CDCl3) H: 10.16 (s, 1H), 8.38 (m, 1H), 7.92 (m, 4H), 7.63-7.47 (m, 1H), 7.43-7.28 (m, 2H), 4.47 (m, 4H), 4.27 (m, 5H), 2.13-1.91 (m, 9H), 1.69-1.39 (m, 21H), 1.00 (m,14H) ppm. 13C NMR (100 MHz; CDCl3) C: 162.4, 159.8, 157.6, 157.5, 149.7, 149.3, 148.8, 148.4,142.9, 140.6, 140.5, 139.9, 132.9, 132.8, 130.3, 127.3, 124.8, 124.5, 123.9, 123.4, 123.4, 117.4,117.2, 116.7, 116.0, 115.9, 110.9, 108.3, 107.0, 106.9, 104.4, 69.8, 69.5, 68.9, 29.2, 29.0, 28.4,28.3, 22.6, 22.6, 14.1 ppm. 19F NMR (282 MHz; CDCl3) F: 109.1 ppm. MALDI+ m/z: 795.6 ([M+1+H]+ 20%), 794.6 ([M+H]+ 65%), 793.6 ([M]+ 100%). IR 1 (neat): 2952 m (CH), 2925 m (CH), 2856 m (CH), 1617 w (CN), 1518 m (benzene ring), 1434 m (benzene ring), 1261 s (CO), 1176 s (CO) cm1. Elemental analysis Found: C, 75.92; H, 8.26; N, 1.74%. C.sub.50H.sub.64FNO.sub.6 requires C, 75.63; H, 8.12; N, 1.76%.
EXAMPLE 10METHOD OF SYNTHESISING COMPOUND 10
[0258] Compound 10 was synthesised using the following method. A slurry of Precursor 2 (100 mg; 0.01 mmol), iodobenzene diacetate (51 mg; 0.16 mmol) and palladium diacetate (1 mg; 0.005 mmol) in a mixture of PhMe (5 mL) and acetic acid (1 mL) in PhMe (5 mL) under an N.sub.2 atmosphere was heated and held at reflux for 72 h. The reaction was then cooled to room temperature and washed with 1M NaOH (1M; 210 mL). The organic phase was evaporated to dryness in vacuo. The solid was then purified via flash column chromatography (60% n-hexane: 40% CH.sub.2Cl.sub.2) to afford Compound 10 as a white solid (64 mg; 66%).
[0259] The name for Compound 10 is 8-methyl-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0260] Compound 10 had the following characterisation data: .sup.1H NMR H: (400 MHz, CDCl.sub.3) 9.94 (1H, s), 7.94 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.85 (1H, s), 4.42 (2H, t, J 6.7), 4.38 (2H, t, J 6.8), 4.30-4.24 (6H, m), 2.81 (3H, s), 1.99 (10H, m), 1.65-1.53 (10H, m), 1.52-1.44 (10H, m), 1.03-0.96 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 162.4, 149.9, 149.4, 149.1, 148.8, 143.2, 140.8, 140.2, 127.2, 125.0, 124.2, 123.9, 123.7, 116.7, 111.6, 108.8, 107.3, 107.2, 102.9, 70.3, 70.2, 69.88, 69.40, 29.60, 29.5, 29.3, 28.8, 28.8, 28.6, 23.0, 15.2, 14.5 ppm. MALDI m/z: 714.5 ([M]+ 100%).
EXAMPLE 11METHOD OF SYNTHESISING COMPOUND 11
[0261] Compound 11 was synthesised using the following method. A solution of Precursor 2 (200 mg, 0.263 mmol) and trimethylamine (0.2 mL, 1.44 mmol) in PhMe (7 mL) was heated at reflux under N.sub.2 for 10 min. 2-Thiophenecarbonyl chloride (0.3 mL, 2.62 mmol) was added and heated under reflux for 90 min. The solution was cooled to room temperature and washed with 1 M HCl (30 mL) and the organic phase extracted with EtOAc (230 mL). The organic phase was dried in vacuo and the resultant black solid was heated at 240 C. for 10 mins before being cooled to room temperature. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 11 as a yellow solid (136 mg; 64%).
[0262] The name for Compound 11 is 2,3,6,11,12-pentakis(pentyloxy)-8-(thiophen-2-yl)triphenyleno[1,2-d]oxazole.
[0263] Compound 11 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.03 (1H, s), 7.99 (1H, dd, J 3.7,1.2), 7.92 (1H, s), 7.89 (1H, s), 7.88 (1H, s), 7.88 (1H, s), 7.58 (1H, dd J 5.0, 1.2), 7.25-7.22 (1H, dd, J 5.0, 3.7), 4.48-4.43 (4H, m), 4.31-4.23 (6H, m), 2.14-1.93 (10H, m), 1.71-1.42 (20H, m), 1.04-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 157.8, 149.8, 149.4, 149.0, 148.6, 143.0, 140.7, 140.1, 130.6, 130.1, 129.7, 128.5, 127.5, 125.0, 124.1, 123.7, 123.6, 116.6, 111.1, 108.5, 107.1, 107.1, 104.0, 70.2, 70.2, 70.1, 69.8, 69.1, 29.6, 29.5, 29.4, 28.9, 28.8, 28.8, 28.6, 23.0, 23.0, 14.6, 14.5, 14.5 ppm. MALDI m/z: 781.5 ([M]+ 100%).
EXAMPLE 12METHOD OF SYNTHESISING COMPOUND 12
[0264] Compound 12 was synthesised using the following method. A solution of Precursor 2 (100 mg, 0.132 mmol), 4-Cyanobenzoyl chloride (109 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 12 as a yellow solid (40 mg, 38%).
[0265] The name for Compound 12 is 4-(2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazol-8-yl)benzonitrile.
[0266] Compound 12 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 9.96 (1H, s), 8.43-8.40 (2H, d, J 8.55), 7.90 (1H, s), 7.89 (1H, s), 7.88 (1H, s), 7.87 (1H, s), 7.83-7.80 (2H, d, J 8.55), 4.43-4.38 (4H, m), 4.30-4.23 (6H, m), 2.12-1.93 (10H, m), 1.67-1.42 (20H, m), 1.04-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 159.3, 150.0, 149.3, 149.1, 148.8, 143.1, 140.6, 140.4, 132.7, 131.4, 127.8, 127.6, 125.0, 123.7, 123.7, 123.4, 118.7, 116.6, 114.4, 111.0, 108.4, 106.9, 106.7, 104.4, 70.2, 70.0, 69.9, 69.8, 69.2, 29.6, 29.5, 29.4, 28.8, 28.8, 28.8, 28.7, 23.0, 14.6, 14.5 ppm. MALDI m/z: 800.4 ([M]+ 100%).
EXAMPLE 13METHOD OF SYNTHESISING COMPOUND 13
[0267] Compound 13 was synthesised using the following method. A solution of 4-(trifluoromethyl)benzoic acid carboxylic acid (248 mg, 1.31 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.157 mmol) in PhMe (5 mL) was heated at 60 C. under N.sub.2 for 30 min. A solution of Precursor 2 (100 mg; 0.132 mmol) in PhMe (2 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH2C12: 60% n-hexane) to afford Compound 13 as a yellow solid (6 mg; 5%).
[0268] The name for Compound 13 is 2,3,6,11,12-pentakis(pentyloxy)-8-(4-(trifluoromethyl)phenyl)triphenyleno[1,2-d]oxazole.
[0269] Compound 13 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.04 (1H, s), 8.48-8.46 (2H, d, J 8.50), 7.92 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.88 (1H, s), 7.83-7.80 (2H, d, J 8.50), 4.47-4.45 (4H, t, J 6.74), 4.31-4.24 (6H, m), 2.14-1.94 (10H, m), 1.70-1.43 (20H, m), 1.05-0.98 (15H, m) ppm. .sup.19F NMR F: (300 MHz, CDC13) 62.9 (s) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 159.3, 150.0, 149.3, 149.1, 148.8, 143.1, 140.6, 140.4, 132.7, 131.4, 127.8, 127.6, 125.0, 123.7, 123.7, 123.4, 118.7, 116.6, 114.4, 111.0, 108.4, 106.9, 106.7, 104.4, 70.2, 70.0, 69.9, 69.8, 69.2, 29.6, 29.5, 29.4, 28.8, 28.8, 28.8, 28.7, 23.0, 14.6, 14.5 ppm. MALDI m/z: 844.5 ([M+H]+ 100%).
EXAMPLE 14METHOD OF SYNTHESISING COMPOUND 14
[0270] Compound 14 was synthesised using the following method. A solution of Precursor 2 (100 mg, 0.132 mmol), 2-iodobenzoyl chloride (175 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 14 as a yellow solid (39.9 mg, 35%).
[0271] The name for Compound 14 is 8-(2-iodophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0272] Compound 14 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.07 (1H, s), 8.20-8.16 (1H, dd, J 7.90, 1.60), 8.18-8.15 (1H, dd, J 7.90, 1.25), 7.95 (1H, s), 7.94 (1H, s), 7.91 (2H, m), 7.58-7.53 (1H, td, J 7.66, 7.63, 1.25), 7.26-7.20 (1H, td, J 7.66, 7.63, 1.60), 4.52-4.44 (4H, m), 4.31-4.25 (6H, m), 2.06-1.94 (10H, m), 1.67-1.41 (20H, m), 1.03-0.92 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 160.9, 149.9, 149.6, 149.2, 149.1, 143.3, 142.0, 140.6, 140.4, 132.5, 132.1, 132.1, 128.5, 127.6, 125.1, 124.1, 124.0, 123.7, 117.2, 111.9, 108.6, 107.3, 107.1, 104.9, 95.0, 70.4, 70.2, 70.2, 70.1, 69.9, 29.6, 29.6, 29.5, 29.5, 28.9, 28.8, 28.7, 23.0, 23.0, 14.5 ppm. MALDI m/z: 901.6 ([M]+ 14%)
EXAMPLE 15METHOD OF SYNTHESISING COMPOUND 15
[0273] Compound 15 was synthesised using the following method. A solution of Precursor 2 (100 mg, 0.132 mmol), 2-chlorobenzoyl chloride (175 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2.
[0274] The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 15 as a yellow solid (52.4 mg, 49%).
[0275] The name for Compound 15 is 8-(2-chlorophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0276] Compound 15 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.06 (1H, s), 8.39-8.34 (1H, m), 7.92-7.90 (4H, m), 7.66 (1H, m), 7.51-7.44 (2H, m), 4.49-4.41 (4H, m), 4.30-4.25 (6H, m), 2.06-1.95 (10H, m), 1.67-1.43 (20H, m), 1.03-0.92 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 158.8, 149.6, 149.4, 148.9, 148.5, 142.9, 140.4, 139.9, 133.5, 131.7, 131.6, 127.3, 127.0, 126.2, 124.8, 123.9, 123.4, 116.8, 110.9, 108.2, 106.9, 104.6, 70.1, 70.0, 69.9, 69.6, 69.1, 29.8, 29.3, 29.3, 29.2, 28.5, 28.4, 22.7, 14.3 ppm. MALDI m/z: 809.7 ([M].sup.+ 95%)
EXAMPLE 16METHOD OF SYNTHESISING COMPOUND 16
[0277] Compound 16 was synthesised using the following method. A solution of Precursor 2 (100 mg, 0.132 mmol), 2-bromobenzoyl chloride (144 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 16 as a yellow solid (25.8 mg, 21%).
[0278] The name for Compound 16 is 8-(2-bromophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0279] Compound 16 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.03 (1H, s), 8.31-8.28 (1H, dd, J 7.91, 1.75), 7.91-7.89 (4H, m), 7.86-7.83 (1H, dd, J 7.91, 1.23), 7.54-7.49 (1H, td, J 7.70, 7.60, 1.23), 7.42-7.37 (1H, td, J 7.70, 7.57, 1.75) 4.49-4.39 (4H, m), 4.31-4.23 (6H, m), 2.06-1.95 (10H, m), 1.64-1.43 (20H, m), 1.03-0.95 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3): 159.5, 149.7, 149.4, 148.9, 148.6, 142.9, 140.3, 135.0, 132.2, 131.8, 128.3, 127.6, 127.4, 124.8, 123.9, 123.6, 123.5, 122.0, 116.9, 111.1, 108.2, 107.0, 104.7, 70.1, 70.0, 69.9, 69.6, 69.4, 29.3, 29.3, 29.2, 28.6, 28.5, 28.4, 22.7, 14.3 ppm. MALDI m/z: 855.7 ([M].sup.+ 31%)
EXAMPLE 17METHOD OF SYNTHESISING COMPOUND 17
[0280] Compound 17 was synthesised using the following method. A solution of 5-bromovaleric acid (773 mg, 4.27 mmol), palladium diacetate (0.005 mmol) and iodobenzene diacetate (0.512 mmol) in PhMe (10 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (325 mg; 0.428 mmol) in PhMe (10 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl2: 60% n-hexane) to afford Compound 17 as a white solid (109 mg; 31%).
[0281] The name for Compound 17 is 8-(4-bromobutyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0282] Compound 17 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 9.95 (1H, s), 7.92 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.84 (1H, s), 4.43-4.34 (4H, m), 4.30-4.24 (6H, m), 3.55-3.50 (2H, t, J 6.29), 3.15-3.10 (2H, t, J 7.05), 2.35 (3H, s), 2.25-1.94 (12H, m), 1.64-1.45 (24H, m), 1.03-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 164.6, 149.6, 149.1, 148.8, 148.4, 142.9, 140.1, 139.7, 127.0, 124.7, 123.8, 123.5, 123.4, 116.3, 111.0, 108.4, 107.0, 102.7, 70.0, 69.9, 69.6, 69.6, 68.9, 33.0, 31.9, 29.3, 29.2, 29.2, 29.1, 28.6, 28.5, 28.4, 28.3, 22.7, 25.3, 22.7, 22.6, 14.2, 14.2, 14.1 ppm. ES+ m/z: 834.4 ([M+H].sup.+ 95%), 836.4 ([M+H]+ 100%).
EXAMPLE 18METHOD OF SYNTHESISING COMPOUND 18
[0283] Compound 18 was synthesised using the following method. A solution of Compound 17 (66 mg, 0.079 mmol) in acetone (10 mL) was heated to 50 C. and stirred under N.sub.2, to this was added a solution of sodium azide (7 mg, 0.111 mmol) in water (5 mL) and left stirring under N.sub.2 for 4 h. After this time a precipitate had formed and the solvent was removed under reduced pressure, the precipitate was then filtered under vacumm and dried to give Compound 18 as an off white solid (59 mg, 94%)
[0284] The name for Compound 18 is 8-(4-azidobutyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0285] Compound 18 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 9.96 (1H, s), 7.94 (1H, s), 7.90 (1H, s), 7.90 (1H, s), 7.87 (1H, s), 4.45-4.40 (2H, t, J 6.70), 4.39-4.35 (2H, t, J 6.67), 4.30-4.24 (6H, m), 3.55-3.51 (2H, t, J 6.31), 3.17-3.12 (2H, t, J 7.11), 2.28-1.93 (12H, m), 1.65-1.41 (24H, m), 1.03-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 165.0, 149.6, 149.9, 149.4, 149.1, 148.7, 143.2, 140.4, 140.0, 127.3, 125.0, 124.1, 123.8, 123.7, 116.7, 111.3, 108.7, 107.3, 103.0, 70.3, 70.3, 69.9, 69.9, 69.2, 33.3, 32.3, 29.6, 29.5, 29.5, 29.4, 28.9, 28.8, 28.7, 28.6, 28.0, 25.6, 23.0, 23.0, 14.6, 14.5, 14.5 ppm. ES+ m/z: 819.5 ([M+Na]+ 100%).
EXAMPLE 19METHOD OF SYNTHESISING COMPOUND 19
[0286] Compound 19 was synthesised using the following method. Compound 17 (21 mg, 0.025 mmol) was dissolved in anhydrous THF (4 mL) to this mixture potassium thioacetate (12 mg, 0.1 mmol) was added and stirred under N.sub.2 for 6 h. The organic phase was then extracted with DCM (10 mL) and washed with water (210 mL). The organic phase was then dried in vacuo and the solid recrystalised with DCM:methanol (1 mL:5 mL). The resultant precipitate was filtered under suction and the solid washed with methanol to give Compound 19 as an off white solid (4 mg, 19%)
[0287] The name for Compound 19 is S-(4-(2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazol-8-yl)butyl) ethanethioate.
[0288] Compound 19 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 9.97 (1H, s), 7.94 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.86 (1H, s), 4.45-4.35 (4H, m), 4.30-4.24 (6H, m), 3.14-3.09 (2H, t, J 7.44), 3.02-2.97 (2H, t, J 7.21), 2.35 (3H, s), 2.18-1.80 (12H, m), 1.65-1.42 (24H, m), 1.03-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 196.0, 165.2, 149.9, 149.4, 149.1, 148.7, 143.2, 140.4, 140.0, 127.2, 125.0, 124.2, 123.8, 123.6, 116.7, 111.4, 108.7, 107.3, 103.1, 70.3, 70.2, 69.9, 69.9, 69.2, 31.0, 30.1, 29.6, 29.5, 29.5, 29.4, 29.4, 29.1, 28.9, 28.8, 28.7, 28.6, 28.5, 26.2, 23.0, 23.0, 14.6, 14.5, 14.5, 14.5 ppm. MALDI m/z: 829.5 ([M]+ 100%).
EXAMPLE 20METHOD OF SYNTHESISING COMPOUND 20
[0289] Compound 22 was synthesised using the following method. A solution of Compound 17 (260 mg, 0.311 mmol), Sodium Tert-butoxide (90 mg, 0.934 mmol), Potassium Iodide (40 mg, 0.311 mmol) and Ethylene Glycol (193 mg, 3.11 mmol) in MeCN (15 mL) was heated to and held at reflux for 48 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The crude solid was dissolved with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL) and then HCl (1M, 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 16 as a yellow solid (84 mg, 36%).
[0290] The name for Compound 20 is 8-(but-3-en-1-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0291] Compound 20 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.00 (1H, s), 7.92 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.84 (1H, s), 6.14-6.00 (1H, ddt, J 16.95, 10.20, 6.45), 5.22 (1H, dd, J 16.95, 1.60), 5.10 (1H, dd, J 10.20, 1.60), 4.43-4.35 (4H, m), 4.30-4.24 (6H, m), 3.22-3.17 (2H, t, J 7.55), 3.17-3.12 (2H, t, J 7.11), 2.86-2.78 (2H, m), 2.08-1.94 (10H, m), 1.62-1.45 (20H, m), 1.03-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 165.0, 149.8, 149.4, 149.1, 148.7, 143.2, 140.4, 140.0, 137.0, 127.2, 125.0, 124.2, 123.8, 123.6, 116.7, 116.3, 111.4, 108.7, 107.3, 107.2, 103.0, 70.3, 70.2, 69.9, 69.9, 69.2, 30.9, 29.6, 29.5, 29.5, 29.3, 28.8, 28.8, 28.7, 28.6, 28.5, 23.0, 22.9, 14.5, 14.5, 14.5 ppm. ES+ m/z: 754.5 ([M+H]+ 100%).
EXAMPLE 21METHOD OF SYNTHESISING COMPOUND 21
[0292] Compound 21 was synthesised using the following method. A solution of decanoic acid (0.132 mg, 0.236 mmol), palladium diacetate (0.005 mmol) and iodobenzene didecanoate (0.235 mmol) in PhMe (10 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg; 0.132 mmol) in PhMe (10 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 21 as a white solid (42 mg; 39%).
[0293] The name for Compound 21 is 8-nonyl-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0294] Compound 21 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.02 (1H, s), 7.93 (1H, s), 7.90 (1H, s), 7.89 (1H, s), 7.84 (1H, s), 4.43-4.36 (4H, m), 4.30-4.24 (6H, m), 3.11-3.06 (2H, t, J 7.52), 2.10-1.94 (12H, m), 1.63-1.29 (32H, m), 1.02-0.97 (15H, m) 0.91-0.87 (3H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 165.9, 149.8, 149.3, 149.0, 148.6, 143.2, 140.4, 140.1, 127.1, 124.9, 124.2, 123.8, 123.6, 123.6, 116.6, 111.3, 108.6, 107.2, 107.1, 102.9, 70.2, 69.9, 69.8, 69.1, 32.3, 29.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.0 28.9, 28.8, 28.6, 27.1 23.1, 23.0, 14.5, 14.5 ppm. ES+ m/z: 826.6 ([M+H]+ 100%).
EXAMPLE 22METHOD OF SYNTHESISING COMPOUND 22
[0295] Compound 22 was synthesised using the following method. A solution of Precursor 2 (100 mg, 0.132 mmol), 4-(dimethylamino)benzoyl chloride (175 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 22 as a yellow solid (19 mg, 18%).
[0296] The name for Compound 22 is N,N-dimethyl-4-(2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazol-8-yl)aniline.
[0297] Compound 22 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.20 (1H, s), 8.27-8.24 (2H, d, J 8.60), 7.94 (1H, s), 7.90-7.85 (3H, m), 6.89-6.86 (2H, d, J 8.60), 4.56-4.45 (4H, m), 4.31-4.24 (6H, m), 3.11 (6H, s), 2.16-1.94 (10H, m), 1.71-1.42 (20H, m), 1.04-0.97 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 162.8, 152.2, 149.7, 149.3, 148.5, 143.1, 141.4, 140.2, 129.3, 127.4, 124.9, 124.5, 124.0, 123.6, 116.5, 112.4, 111.5, 108.6, 107.3, 107.2, 103.4, 70.2, 70.2, 69.9, 69.2, 40.9, 29.6, 29.6, 29.5, 29.4, 29.0, 28.8, 28.8, 28.7, 23.0, 23.0, 14.7, 14.5 ppm. ES+ m/z: 819.7 ([M]+ 100%).
EXAMPLE 23METHOD OF SYNTHESISING COMPOUND 23
[0298] Compound 23 was synthesised using the following method. A solution of 4-nitrobenzoic acid (1 g, 6 mmol), palladium diacetate (0.005 mmol) and (diacetoxyiodo)benzene (51 mg, 0.157 mmol) in PhMe (10 mL) was heated at 70 C. under N.sub.2 for 20 min. A solution of Precursor 2 (100 mg; 0.132 mmol) in PhMe (10 mL) was added and heated under reflux for 48-72 h, whilst stirring. The solution was cooled to room temperature and diluted with CH.sub.2Cl.sub.2 (20 mL). The organic phase was washed with aqueous NaOH (1M; 220 mL), separated and the organic phase was dried in vacuo. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 23 as an off-white solid (74 mg; 69%).
[0299] The name for Compound 23 is 8-(4-nitrophenyl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0300] Compound 23 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 9.66 (1H, s), 8.14-8.05 (4H, m), 7.74 (1H, s), 7.73 (1H, s), 7.70 (1H, s), 7.67 (1H, s), 4.30-4.19 (10H, m), 2.04-1.94 (10H, m), 1.63-1.47 (20H, m), 1.05-1.00 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 158.9, 150.0, 149.3, 149.1, 148.8, 143.0, 140.6, 140.4, 132.8, 127.8, 127.5, 125.0, 124.0, 123.6, 123.5, 123.3, 116.5, 110.8, 108.3, 106.8, 106.4, 104.3, 70.2, 69.9, 69.8, 69.7, 69.1, 29.6, 29.6, 29.5, 29.4, 28.9, 28.8, 28.8, 28.7, 23.0, 14.6, 14.5 ppm. MALDI m/z: 820.5 ([M]+ 100%).
EXAMPLE 24METHOD OF SYNTHESISING COMPOUND 24
[0301] Compound 24 was synthesised using the following method. A solution of (diacetoxyiodo)benzene (51 mg, 0.157 mmol) and acetylsalicylic acid (550 mg, 3.031 mmol) in toluene (4 mL) was heated to 80 C. and stirred for 10 mins under N.sub.2. Then Precursor 2 (100 mg, 0.131 mmol) was added to form a black solution which was then stirred for a further 10 mins. A solution of palladium diacetate (1 mg, 5 mol %) and acetylsalicyclic acid (553 mg, 3.197 mmol) in toluene (4 mL) was heated to 110 C. and stirred for 10 mins under N.sub.2 before being combined with the black solution. The resultant solution was left stirring at 110 C. for 72 h under N.sub.2. The crude black solution was dried in vaccuo and purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane). The crude material was then evaporated to dryness in vacuo and then dissolved in a mixture of MeCN (10 mL) and 1M NaOH (10 mL). The solution was heated to 80 C. for 2 h. After cooling to room temperature the product was acidified using 1M HCl (20 mL) and extracted into CH.sub.2Cl.sub.2 (310 mL). The combined organic layer was evaporated to dryness in vacuo to afford Compound 24 as a white solid (2 mg. 2%)
[0302] The name for Compound 24 is 2-(2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazol-8-yl)phenol.
[0303] Compound 24 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 11.42 (1H, s), 9.35 (1H, s), 8.20-8.17 (1H, dd, J 8.01, 1.67), 7.90 (1H, s), 7.89 (1H, s), 7.88 (1H, s), 7.87 (1H, s), 7.52-7.46 (1H, ddd, J 8.51, 7.22, 1.67), 7.18-7.14 (1H, dd, J 8.51, 1.08), 7.08-7.05 (1H, ddd, J 8.01, 7.22, 1.08), 4.47-4.42 (2H, t, J 6.65), 4.39-4.35 (2H, t, J 6.71), 4.30-4.19 (6H, m), 2.09-1.94 (10H, m), 1.71-1.43 (20H, m), 1.05-0.98 (15H, m) ppm. MALDI m/z: 791 ([M]+ 100%).
EXAMPLE 25METHOD OF SYNTHESISING COMPOUND 25
[0304] Compound 25 was synthesised using the following method.
[0305] Precursor 3 was synthesised using the following method. A solution of 2,3,6,7,10,11-hexabutoxy-1-nitrotriphenylene (1.70 g, 2.79 mmol), Sodium borohydride (1.70 g, 45.1. mmol) and Nickel(II) chloride hexahydrate (4.45 g, 18.7 mmol) in a 50/50 mix of MeO and THF (40 mL) was stirred at room temperature for 5 h under N.sub.2. The crude black solid was then filtered and washed with CHCl.sub.3 and the filtrate evaporated to dryness in vacuo to afford Precursor 3 as a brown solid (1.6 g, 85%).
[0306] The name for Precursor 3 is 2,3,6,7,10,11-hexabutoxytriphenylen-1-amine
[0307] Precursor 3 had the following characterization data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 8.82 (1H, s), 7.83 (1H, s), 7.80 (1H, s), 7.78 (1H, s), 7.37 (1H, s), 4.57 (2H, s), 4.29-4.09 (12H, m), 2.01-1.81 (12H, m), 1.67-1.52 (12H, m), 1.13-0.94 (18H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 151.0, 149.5, 148.9, 148.0, 147.6, 138.4, 135.6, 127.0, 124.7, 124.5, 124.1, 124.0, 114.0, 110.3, 108.5, 108.2, 107.1, 97.4, 72.9, 69.7, 69.4, 69.1, 68.4, 32.7, 31.7, 31.7, 31.6, 31.6, 19.6, 19.6, 19.5, 19.5, 14.1 ppm. MALDI m/z: 675.8 ([M]+ 100%).
[0308] A solution of Precursor 3 (100 mg, 0.148 mmol), 2-napthoyl chloride (141 mg, 0.658 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was heated to and held at reflux for 18 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 25 as a yellow solid (21 mg, 19%).
[0309] The name for Compound 25 is 2,3,6,11,12-pentabutoxy-8-(naphthalen-2-yl)triphenyleno[1,2-d]oxazole.
[0310] Compound 25 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.01 (1H, s), 8.68 (1H, s), 8.31-8.27 (1H, dd, J 8.57, 1.65), 7.96-7.87 (3H, m), 7.80-7.79 (3H, m), 7.70 (1H, s), 7.58-7.55 (2H, m), 4.45-4.40 (2H, t, J7.01), 4.38-4.34 (2H, t, J6.67), 4.28-4.19 (6H, m), 2.15-1.91 (10H, m), 1.79-1.59 (10H, m), 1.18-1.07 (15H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 161.6, 149.7, 149.3, 149.0, 148.5, 143.1, 140.8, 140.4, 134.9, 133.4, 129.2, 128.3, 127.8, 127.3, 127.1, 125.0, 124.9, 124.4, 124.1, 123.7, 123.6, 116.6, 111.3, 108.4, 107.1, 106.9, 103.7, 69.8, 69.6, 69.5, 68.9, 31.9, 31.9, 19.9, 19.8, 19.8, 14.5, 14.4, 14.4 ppm. MALDI m/z: 755.1 ([M]+ 100%).
EXAMPLE 26METHOD OF SYNTHESISING COMPOUND 26
[0311] Compound 26 was synthesised using the following method. A solution of Precursor 4 (135 mg, 0.174 mmol) and palladium diacetate (0.0005 mmol) in PhMe (7 mL) was heated at reflux under N.sub.2 for 10 min. 2-flourobenzoyl chloride (0.02 mL, 0.174 mmol) was added and heated under reflux for 40 h. The solution was cooled to room temperature and dried in vacuo and the resultant black solid was heated at 240 C. for 10 minutes before being cooled to room temperature. The crude black solid was purified by flash column chromatography (silica; 40% CH.sub.2Cl.sub.2: 60% n-hexane) to afford Compound 26 as an off-white solid (6 mg; 4%).
[0312] The name for Compound 26 is 2,9-bis(2-fluorophenyl)-4,7,12,13-tetrakis(pentyloxy)triphenyleno[1,2-d:8,7-d]bis(oxazole).
[0313] Compound 26 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.09 (2H, s), 8.38-8.32 (2H, td, J 7.56, 7.52, 1.78), 7.82 (2H, m), 7.58 (2H, m), 7.36-7.31 (2H, m), 7.29-7.25 (2H, m), 4.48-4.39 (8H, m), 2.16-1.96 (8H, m), 1.70-1.44 (16H, m), 1.05-1.00 (12H, m) ppm. .sup.19F NMR F: (300 MHz, CDCl.sub.3) 108.9 (s) ppm. MALDI m/z: 842.5 ([M]+ 100%).
EXAMPLE 27METHOD OF SYNTHESISING COMPOUND 27
[0314] Compound 27 was synthesised using the following method. A solution of 4-Carboxybenzo-15-crown-5 (600 mg, 1.92 mmol), Oxalyl chloride (2.0 mL, 23.6 mmol) and Dimethylformamide (0.01 ml, 0.129 mmol) was heated and held at reflux for 10 minutes under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. A solution of Precursor 2 (100 mg, 0.132 mmol) and N,N-Diisopropylethylamine (0.1 mL, 0.574 mmol) in PhMe (5 mL) was added. The reaction was then heated and held at reflux for 72 h under N.sub.2. The reaction was cooled to room temperature and then evaporated to dryness in vacuo. The solid was then heated and held at 240 C. for 15 mins under N.sub.2. The crude black solid was then cooled to room temperature and purified via flash column chromatography (silica, 10% EtOAc: 90% n-hexane) to afford compound 27 as a brown solid (22 mg, 17%).
[0315] The name for Compound 27 is 8-(2,3,5,6,8,9,11,12-octahydrobenzo[b][1,4,7,10,13]pentaoxacyclopentadecin-15-yl)-2,3,6,11,12-pentakis(pentyloxy)triphenyleno[1,2-d]oxazole.
[0316] Compound 27 had the following characterisation data: .sup.1H NMR H: (300 MHz, CDCl.sub.3) 10.10 (1 H, s), 8.04-7.80 (6 H, m), 6.99 (1 H, d, J 8.35), 4.53-4.38 (4 H, m), 4.33-4.17 (10 H, m), 4.06-3.90 (4 H, m), 3.89-3.73 (8 H, m), 2.10-1.88 (10 H, m), 1.69-1.44 (20 H, m), 1.07-0.92 (15 H, m) ppm. .sup.13C NMR C: (100 MHz, CDCl.sub.3) 161.6, 152.1, 149.6, 149.1, 148.9, 148.4, 142.9, 140.7, 140.1, 127.2, 124.7, 124.0, 123.6, 123.4, 121.7, 120.5, 116.4, 113.2, 112.9, 111.1, 108.3, 107.0, 103.4, 71.3, 70.6, 70.5, 70.0, 70.0, 69.9, 69.6, 69.5, 69.2, 68.9, 68.7, 29.8, 29.4, 29.3, 29.3, 28.7, 28.5, 28.4, 22.8, 22.7, 14.3, 14.3 ppm. MALDI m/z: 965.9 ([M]+ 100%).
EXAMPLE 28METHOD OF SYNTHESISING COMPOUND 28
[0317] Compound 28 was synthesised using the following method. A solution of Compound 2 (60 mg, 0.077 mmol) in degassed dichloromethane (5 mL) was stirred in a nitrogen purged 2 neck flask under nitrogen atmosphere at 20 C. Boron tribromide (1M solution in dichloromethane, 387 L, 0.385 mmol, 5 eq) was added via syringe through a Suba-Seal and the dark yellow solution was stirred for at room temperature for 24 h. Water (40 mL) was added to quench the reaction and the product was extracted with dichloromethane (10 mL), washed with water (220 mL) and dried over MgSO.sub.4. The organic phase was evaporated to dryness and purified by column chromatography (Silica: 5% Ethyl acetate: Hexane) to afford Compound 28 as a brown solid (10 mg, 6%).
[0318] The name for Compound 28 is 2,3,11,12-tetrakis(pentyloxy)-8-phenyltriphenyleno[1,2-d]oxazol-6-ol.
[0319] Compound 28 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.09 (1H, s), 8.48 (2H, dd, J 6.86, 2.85 Hz), 7.94 (1H, s), 7.90 (1H, s), 7.88 (1H, s), 7.83 (1H, s), 7.59-7.56 (3H, m), 5.95 (1H, s br), 4.48 (2H, t, J 6.60 Hz), 4.33 (2H, t, J 6.51 Hz), 4.26-4.24 (4H, m), 2.06-1.93 (8H, m), 1.64-1.43 (16H, m), 1.01-0.97 (12H, m) ppm. ES.sup.+MS m/z: 728.39 ([M+Na].sup.+ 25%), 707.41 ([M+H+1].sup.+ 30%), 706.41 ([M+H].sup.+ 85%).
EXAMPLE 29METHOD OF SYNTHESISING COMPOUND 29
[0320] Compound 29 was synthesised using the following method. Compound 2 (250 mg, 0.322 mmol) was disolved in dry dichloromethane (10 mL) and stired at 0 C. under a nirtogen atmosphere. 0.01M solution of Br.sub.2 in dichloromethane (144 mL, 1.449 mmol) was then added over 2 hours (436 mL) and monitered by TLC. The reaction was quenched by addition of saturated sodium metabisulfate solution (100 mL). The product was extracted with dichloromethane (30 mL) washed with water (330 mL), dried over MgSO.sub.4 and evaporated to dryness. The crude product was then purified by column chromatography (Silica 40% dichloromethane:hexane) to yield Compound 29 as a yellow solid (170 mg, 62%).
[0321] The name for Compound 29 is 1-bromo-2,3,6,11,12-pentakis(pentyloxy)-8-phenyltriphenyleno[1,2-d]oxazole.
[0322] Compound 29 had the following characterisaton data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 10.06 (1H, s), 8.71 (1H, s), 8.56 (1H, s), 8.34-8.31 (2H, m), 7.60-7.58 (4H, m), 4.59 (2H, t J 6.5 Hz), 4.41 (2H, t J 6.8 Hz), 4.26-4.20 (6H, m), 2.06-1.90 (10H, m), 1.64-1.42 (20H, m), 1.02-0.94 (15H, m) ppm.
EXAMPLE 30METHOD OF SYNTHESISING COMPOUND 30
[0323] Compound 30 was synthesised using the following method. Compound 29 (170 mg, 0.199 mmol), K.sub.2CO.sub.3 (410 mg, 2.97 mmol) and Pd(PPh.sub.3).sub.4 (30 mg, 0.026 mmol) were dissolved in degassed 5 : 1 tertahydrofuran:Water mix (4 mL) under nitrogen atmosphere. (4-hydroxyphenyl)boronic acid (140 mg, 1.02 mmol) was then added and the reaction was heated to reflux under N.sub.2 for 24 h. The product was extracted with dichloromethane (30 mL), washed with water (330 mL) and evaporated to dryness. The crude product was purified by column cromatography (Silica DCM:Hexane) to yield impure Compound 30 as a brown solid.
[0324] The name for Compound 30 is 4-(2,3,6,11,12-pentakis(pentyloxy)-8-phenyltriphenyleno[1,2-d]oxazol-1-yl)phenol.
[0325] Compound 30 had the following characterisation data: TOF LD.sup.+ m/z: 869.49 ([M+1].sup.+ 70%), 868.52 ([M].sup.+ 70%).
EXAMPLE 31METHOD OF SYNTHESISING COMPOUND 31
[0326] Compound 31 was synthesised using the following method. Compound 10 (50.7 mg, 0.071 mmol) was added to a 2 neck round bottom flask, which was purged with nitrogen for 15 minutes. Dry dichloromethane (20 mL) was then added via syringe through a Suba-Seal and the brown stirring solution was cooled to 78 C. Boron tribromide (1M solution in dichloromethane, 391 L, 0.391 mmol, 5.5 equivalents) was added via syringe through a Suba-Seal and the reaction was stirred for 4 h. The reaction mixture was poured over crushed ice and stirred until the ice had fully melted, 4 drops of hydrochloric acid (1M) were added and the product was extracted with ethyl acetate, washed with water (220 mL), and dried over MgSO.sub.4 and evaporated to dryness. The crude product was used without further purification.
[0327] The name for Compound 31 is 8-methyltriphenyleno[1,2-d]oxazole-2,3,6,11,12-pentaol.
[0328] Compound 31 had the following characterisation data: ES.sup.+ MS m/z: 503.26 ([M+2(OC.sub.5H.sub.11)].sup.+ 50%), 433.17 ([M+(OC.sub.5H.sub.11)].sup.+ 100%), 363.08 ([M].sup.+ 10%).
EXAMPLE 32METHOD OF SYNTHESISING COMPOUND 32
[0329] Crude Compound 31 (26 mg, 0.071 mmol), potassium carbonate (74 mg, 0.533 mmol), potassium iodide (6 mg, 0.036 mmol) was dissolved in dry acetonitrile (35 mL). 1(-2-Bromoethoxy)-2-(2-methoxyethoxy)ethane (132 L, 0.533 mmol) was then added via pipette and the reaction was heated to reflux and stirred under a CaCl.sub.2 drying tube for 20 hours. The reaction was cooled to room temperature and the product was extracted with ethyl acetate (20 mL), washed with water (320 mL), brine (220 mL) and dried over MgSO.sub.4 to yield crude Compound 32 as a brown solid.
[0330] The name for Compound 32 is 2,3,6,12-tetrakis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-8-methyl-11-(pentyloxy)triphenyleno[1,2-d]oxazole.
[0331] Compound 32 had the following characterisation data: ES.sup.+MS m/z: 1017.51 ([M].sup.+ 100%).
[0332] Advantageously, Compound 32 is water soluble.
EXAMPLE 33METHOD OF SYNTHESISING COMPOUND 33
[0333] Referring now to
[0334] Compound 33 was synthesised from Precursor 5 in the following method. The starting material to form Precursor 5 was obtained using the method described in J. Mater. Chem. C, 2017,5, 669-682 (DOI: 10.1039/C6TC04530H).
[0335] Precursor 5 was synthesised in the following method. 5,6-dimethoxy-2,3,8,9,12,13-hexakis(pentyloxy)dibenzo[fg,op]tetracene (681 mg, 0.775 mmol) was dissolved in diethyl ether (20 ml) and then acetic acid (1.33 ml, 23.24 mmol, 30 eqiv) was added and the mixture stirred at room temperature in a nitrogen atmosphere for 10 minutes before the addition of fuming nitric acid (65 L, 1.55 mmol, 2 equiv) was added. The reaction mixture was stirred under nitrogen for 20 minutes before the further addition of nitric acid (30 L, 0.715 mmol, 0.92 equiv) and the reaction mixture was left for 20 minutes stirring at room temperature. The mixture was then quenched with water (10 ml) and the organic phase was washed with NaOH (1 M, 230 mL) and then dried in vacuo to provide Precursor 5 as a black solid (680 mg, 95%). This was used in the next step with no further purification.
[0336] The name for Precursor 5 is 5,6-dimethoxy-1-nitro-2,3,8,9,12,13-hexakis(pentyloxy)dibenzo[fg,op]tetracene.
[0337] Precursor 5 had the following characterisation data: .sup.1H NMR (400 MHz, CDCl3) 9.16 (s, 1H), 9.01 (s, 1H), 7.95 (s, 1H), 7.84 (s, 1H), 7.58 (s, 1H), 4.53 (t, J=6.7 Hz, 2H), 4.32 (t, J=5.1 Hz, 2H), 4.29 (t, J=5.3 Hz, 2H), 4.18-4.14 (m, 2H), 4.14 (s, 3H), 4.13 (s, 3H), 3.95 (t, J=6.8 Hz, 2H), 3.95 (t, J=7.0 Hz, 2H), 2.11-1.82 (m, 12H), 1.69-1.29 (m, 24H), 1.08-0.84 (m, 18H). .sup.13C NMR (101 MHz, CDCl3) 151.9, 149.6, 149.3, 148.7, 148.1, 147.9, 144.4, 143.2, 141.5, 124.9, 124.8, 124.7, 124.4, 123.1, 123.1, 122.3, 119.4, 118.6, 116.0, 109.5, 109.3, 107.6, 107.3, 104.9, 76.3, 74.5, 74.0, 69.5, 68.9, 68.8, 55.8, 30.3, 30.3, 29.9, 29.2, 29.0, 28.8, 28.4, 28.3, 28.2, 28.1, 22.6, 22.6, 22.6, 14.1, 14.0, 14.0. MALDI.sup.+ m/z: 924.82 ([M+H].sup.+ 30%).
[0338] Precursor 6 was synthesised in the following method. Precursor 5 (680 mg, 0.736 mmol) and NiCl.sub.2. 6H.sub.2O (552 mg, 2.33 mmol, 3 equivalents) were dissolved in THF:MeOH (20 mL, 5:4 ratio), to make a yellow solution, and then NaBH4 (586 mg, 15.5 mmol, 20 equivalents) was added over 15 minutes. The black reaction mixture was left stirring under a nitrogen atmosphere for 40 minutes after which time it was diluted with chloroform and the precipitate was gravity filters to leave a brown organic phase, which was then dried in vacuo to provide Precursor 6 as brown solid (614 mg, 93%).
[0339] The name for Precursor 6 is 5,6-dimethoxy-2,3,8,9,12,13-hexakis(pentyloxy)dibenzo[fg,op]tetracen-1-amine.
[0340] Precursor 6 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl3) 9.09 (s, 1H), 8.98 (s, 1H), 8.67 (s, 1H), 7.97 (s, 1H), 7.90 (s, 1H), 4.76 (s, 2H), 4.40 (t, J=6.8 Hz, 2H), 4.34 (t, J=6.5 Hz, 2H), 4.28 (t, J=6.6 Hz, 2H), 4.20 (t, J=6.6 Hz, 2H), 4.11 (s, 3H), 4.08 (s, 3H), 3.99 (t, J=7.0 Hz, 2H), 3.93 (t, J=7.0 Hz, 2H), 2.07-1.88 (m, 12H), 1.66-1.34 (m, 24H), 1.06-0.88 (m, J=22.0, 12.0, 7.1 Hz, 18H). .sup.13C NMR (101 MHz, CDCl.sub.3) 151.2, 148.5, 148.2, 148.0, 146.8, 143.8, 139.8, 136.9, 125.4, 125.0, 124.5, 124.4, 123.6, 123.5, 122.6, 120.5, 113.9, 111.8, 110.0, 109.4, 108.6, 108.4, 104.3, 73.9, 73.8, 69.7, 69.2, 69.0, 55.7, 30.4, 30.3, 29.7, 29.3, 29.1, 29.0, 28.5, 28.4, 28.3, 22.7, 22.6, 22.6, 14.1, 14.0. MALDI.sup.+ m/z: 893.79 ([M+H].sup.+ 100%).
[0341] Precursor 7 was synthesised in the following method. Precursor 6 (147 mg, 0.181 mmol) was dissolved in dry dichloromethane (20 mL) and dry acetonitrile (20 mL). The solution was cooled to 0 C. under a nitrogen atmosphere then tent-butyl nitrite (34 L, 0.309 mmol, 1.7 equivalents) and TMSN3 (36 L, 0.273 mmol, 1.5 equivalents) were added and the reaction mixture stirred 0 C. for 10 minutes and then at room temperature for 20 minutes. The solution was then dried in vacuo and purified via flash column chromatography (silica,30% DCM, 70% n-hexane) to provide Precursor 7 as a while solid (120 mg, 72%).
[0342] The name for Precursor 7 is 1-azido-5,6-dimethoxy-2,3,8,9,12,13-hexakis(pentyloxy)dibenzo[fg,op]tetracene.
[0343] Precursor 7 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl3) 9.12 (s, 1H), 9.03 (s, 1H), 8.98 (s, 1H), 8.01 (s, 1H), 7.89 (s, 1H), 4.45 (t, J=6.7 Hz, 2H), 4.38-4.32 (m, 2H), 4.29 (t, J=6.0 Hz, 2H), 4.11 (s, 3H), 4.09 (s, 3H), 4.01 (t, 2H), 3.94 (t, J=6.6 Hz, 2H), 2.13-1.84 (m, 12H), 1.69-1.32 (m, 24H), 1.04-0.87 (m, 18H). .sup.13C NMR (101 MHz, CDCl3) 151.57, 148.85, 148.03, 147.99, 147.89, 147.88, 146.27, 144.06, 127.30, 125.39, 124.82, 123.99, 123.85, 123.33, 123.17, 122.79, 120.18, 119.39, 117.58, 112.56, 109.38, 109.10, 107.51, 104.74, 75.30, 74.36, 73.97, 69.64, 69.14, 69.01, 55.81, 30.39, 30.32, 29.53, 29.25, 29.08, 28.94, 28.45, 28.33, 28.23, 28.22, 22.70, 22.62, 22.57, 14.10, 14.01.
[0344] Compound 33 was synthesised using the following method. Precursor 7 (100 mg; 0.13 mmol) was dissolved in dry toluene (5 mL) was added to a flask containing rhodium octanoate dimer (5 mg; 0.01 mmol), under a nitrogen atmosphere. This mixture was then heated to reflux and stirred for 20 hours. The reaction was cooled to room temperature and then dried in vacuo, the solid was then purified via flash column chromatography (silica; 95% n-hexane: 5% ethyl acetate) to provide Compound 33 as a white solid (58 mg, 50%).
[0345] The name of Compound 33 is 2-butyl-12,13-dimethoxy-5,6,9,10,15-pentakis(pentyloxy)dibenzo[4,5:9,10]pyreno[1,2-d]oxazole.
[0346] Compound 33 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl3) 10.08 (s, 1H), 9.28 (s, 1H), 9.15 (s, 1H), 8.16 (s, 1H), 8.02 (s, 1H), 4.42 (t, J=6.0 Hz, 2H), 4.37 (d, J=5.8 Hz, 2H), 4.35-4.29 (m, J=6.7, 3.3 Hz, 4H), 4.12 (s, 3H), 4.11 (s, 3H), 3.98 (t, J=6.9 Hz, 2H), 3.18 (t, J=7.5 Hz, 2H), 2.09-1.92 (m, 10H), 1.67-1.36 (m, 24H), 1.07-0.90 (m, 18H). .sup.13C NMR (101 MHz, CDCl3) 166.1, 151.3, 149.5, 148.8, 147.8, 147.7, 144.0, 142.4, 138.4, 137.1, 125.5, 124.9, 124.1, 124.0, 123.7, 123.5, 123.0, 119.9, 118.8, 116.1, 111.3, 109.6, 109.4, 107.1, 104.8, 74.5, 74.0, 69.8, 69.0, 68.8, 55.8, 55.7, 30.3, 30.1, 29.3, 29.1, 28.9, 28.7, 28.5, 28.4, 28.3, 28.2, 22.6, 22.5, 22.3, 14.1, 14.0, 13.8. MALDI.sup.+ m/z: 889.16 ([M+H].sup.+ 100%).
EXAMPLE 34METHOD OF SYNTHESISING COMPOUND 34
[0347] Precursor 6 (47 mg; 0.053 mmol), benzoyl chloride (30 L, 0.265 mmol, 5 equivalents), and diisopropylehtylamine (46 L, 0.265 mmol, 5 equiv) were dissolved in dry toluene (5 mL) and the mixture was heated to reflux under a nitrogen atmosphere. The reaction mixture was stirred for 1 hour at which point the mixture was dried in vacuo then the solid was heated to 240 C. for 10 minutes. The reaction was cooled to room temperature and the solid was then purified via flash column chromatography (silica; 40% DCM, 60% n-hexane) to afford Compound 34 a white solid (16 mg, 33%).
[0348] The name of Compound 34 is 12,13-dimethoxy-5,6,9,10,15-pentakis(pentyloxy)-2-phenyldibenzo[4,5:9,10]pyreno[1,2-d]oxazole.
[0349] Compound 34 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl3) 9.29 (s, 1H), 9.19 (s, 1H), 8.48-8.43 (m, 2H), 8.17 (s, 1H), 8.03 (s, 1H), 7.65-7.59 (m, 3H), 4.53 (t, J=6.9 Hz, 2H), 4.44-4.33 (m, 6H), 4.14 (s, 3H), 4.12 (s, 3H), 3.99 (t, J=6.9 Hz, 2H), 2.15-1.90 (m, 10H), 1.71-1.36 (m, 24H), 1.06-0.80 (m, 18H). .sup.13C NMR (101 MHz, CDCl3) 166.6, 161.8, 151.4, 149.5, 148.9, 147.9, 147.9, 144.1, 142.5, 138.5, 137.7, 132.9, 131.5, 129.5, 129.0, 128.4, 127.6, 127.4, 125.6, 124.8, 124.3, 124.0, 123.8, 123.5, 123.3, 119.8, 119.7, 116.4, 111.3, 109.7, 109.4, 106.9, 104.8, 74.7, 74.1, 69.8, 69.0, 64.5, 55.8, 55.7, 30.4, 30.2, 29.7, 29.3, 29.1, 28.9, 28.5, 28.5, 28.4, 25.6, 22.6, 22.5, 14.2, 14.1, 14.1, 14.1, 14.0. ES.sup.+ m/z: 910.54 ([M+H].sup.+ 100%).
EXAMPLE 35METHOD OF SYNTHESISING COMPOUND 35
[0350] Precursor 6 (100 mg; 0.111 mmol) 4-cyanobenzoyl chloride (92 mg, 0.555 mmol, 5 equiv), and diisopropylehtylamine (90 L, 0.555 mmol, 5 equiv) were dissolved in dry toluene (5 mL) and the mixture was heated reflux under a nitrogen atmosphere. The reaction mixture was stirred for 1 hour at which point the mixture was dried in vaccuo then the solid was heated to 240 C. for 10 minutes. The reaction was cooled to room temperature and the solid was then purified via flash column chromatography (silica; 40% DCM, 60% n-hexane) to afford Compound 35 as a white solid (17 mg, 16%).
[0351] The name of Compound 35 is 4-(12,13-dimethoxy-5,6,9,10,15-pentakis(pentyloxy)dibenzo[4,5:9,10]pyreno[1,2-d]oxazol-2-yl)benzonitrile.
[0352] Compound 35 had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) 10.02 (s, 1H), 9.27 (s, 1H), 9.15 (s, 1H), 8.43 (d, J=8.3 Hz, 2H), 8.13 (s, 1H), 7.99 (s, 1H), 7.84 (d, J=8.3 Hz, 2H), 4.45 (t, J=6.8 Hz, 2H), 4.36 (dt, J=13.0, 6.4 Hz, 6H), 4.14 (s, 3H), 4.12 (s, 3H), 3.97 (t, J=6.9 Hz, 2H), 2.12-1.90 (m, 10H), 1.65-1.38 (m, 24H), 1.06-0.88 (m, 18H). .sup.13C NMR (100 MHz, CDCl.sub.3) 159.8, 151.9, 149.9, 149.5, 148.5, 148.3, 144.6, 143.0, 138.6, 137.6, 133.0, 131.5, 128.0, 125.8, 124.8, 124.4, 123.9, 123.8, 123.8, 121.1, 119.9,118.6, 117.0,114.7, 111.5,110.1, 109.8, 107.1, 105.2, 75.1, 74.4, 70.1, 69.3, 56.2, 56.1, 30.7, 30.5, 30.0, 29.6, 29.5, 29.3, 28.9, 28.8, 28.7, 28.7, 23.0, 22.9, 22.9, 14.6, 14.5, 14.4. MALDI.sup.+ m/z: 934.55 ([M+H].sup.+ 100%).
Method of Synthesising Compound XX
[0353] Compound XX was synthesised using the following method. Compound 404 (wherein R=C.sub.5H.sub.11) shown in
[0354] The name for Compound XX is 1-bromo-8-nitro-2,3,6,7,10,11-hexakis(pentyloxy)triphenylene.
[0355] Compound XX had the following characterisation data: .sup.1H NMR (300 MHz, CDCl.sub.3) H: 8.78 (1H, s), 7.79 (1H, s), 7.69 (1H, s), 7.42 (1H, s), 4.25-4.17 (8H, m), 4.12-4.06 (4H, m), 1.97-1.77 (12H, m), 1.57-1.40 (24H, m), 1.00-0.93 (18H, m) ppm. ES.sup.+MS m/z: 867.43 ([M].sup.+ 25%).
[0356] It is understood that the method of brominating Compound XX may be applied to the phenoxazoles of the invention, for example, to add further functionality to the molecules.
Properties of Triphenylene Derivative Series 100
[0357] The triphenylene derivative series 100 of the present invention exhibits a number of advantageous properties that are useful in many applications. Some of these advantageous properties are demonstrated below in a non-limiting way.
[0358] Referring to
[0359] There is shown the absorption spectra (designated with the prefix A) for Compounds 1 to 6 (A1, A2, A3, A4, A5, A6) and the emission spectra (designated with the prefix E) for Compounds 1 to 6 (E1, E2, E3, E4, E5, E6). The full emission spectrum E6 for Compound 6 could not be detected due to equipment limitations.
[0360] The absorption spectra A403 and emission spectra E403 of intermediate compound 403 shown in
[0361] Referring also to Table 1, there is shown luminescent data for the Compounds 1 to 6. There is shown the maximum absorption values max (nm), the maximum emission values max (nm), the pseudo Stokes shift pSS (cm.sup.1), the quantum yield , and the brightness (M.sup.1 cm.sup.1). The luminescent data shown in Table 1 was recorded for each of the Compounds 1 to 6 individually in ethyl acetate, octan-1-ol, and acetonitrile.
TABLE-US-00001 TABLE 1 Luminescent data for Compounds 1 to 6 Solvent .sub.r Viscosity (cP) Compound 1 Compound 2 Compound 3 Compound 4 Compound 5 Compound 6 Ethyl 6.0 0.45 Absorption .sub.max (nm) 281 270 272 275 272 253 acetate Emission .sub.max (nm) 367 467 494 510 536 594 pSS (cm.sup.1) 8300 15600 16500 16800 18100 22700 0.18 0.01 0.46 0.04 0.55 0.05 0.48 0.04 0.51 0.04 Brightness (M.sup.1 cm.sup.1) 29 5 51 5 92 9 56 5 53 5 Octan-1-ol 10.3 7.36 Absorption .sub.max (nm) 281 271 272 275 270 255 Emission .sub.max (nm) 367 473 497 515 526 384 pSS (cm.sup.1) 8300 15800 16600 17000 18000 13200 0.30 0.03 0.61 0.06 0.71 0.07 0.55 0.05 0.56 0.05 Brightness (M.sup.1 cm.sup.1) 36 7 64 6 91 9 67 7 50 5 Acetonitrile 37.5 0.38 Absorption .sub.max (nm) 281 270 273 275 270 253 Emission .sub.max (nm) 367 492 524 543 592 630 pSS (cm.sup.1) 8300 16700 17600 18000 20200 23650 0.20 0.02 0.46 0.04 0.51 0.05 0.36 0.04 0.21 0.02 Brightness (M.sup.1 cm.sup.1) 12 2 38 4 44 4 30 3 No value could be obtained No value could be obtained due to poor solubility and therefore no data.
[0362] Referring also to Table 2, there is shown further luminescent data for Compounds 1 to 6. There is shown the molar extinction coefficients (E10.sup.3) (M.sup.1 cm.sup.1) alongside the maximum absorption values max (nm), recorded at a concentration of 110.sup.7 mol dm.sup.3 individually in ethyl acetate, octan-1-ol, and acetonitrile.
TABLE-US-00002 TABLE 2 Luminescent Absorption data for Compounds 1 to 6 Ethyl acetate Octan-1-ol Acetonitrile 10.sup.3 max 10.sup.3 max 10.sup.3 max (M.sup.1 cm.sup.1) (nm) (M.sup.1 cm.sup.1) (nm) (M.sup.1 cm.sup.1) (nm) Compound 160 15 278 120 12 278 58 6 278 1 Compound 110 11 270 105 10 271 66 6 271 2 Compound 117 12 275 122 12 275 84 8 275 3 Compound 164 16 272 128 13 272 85 9 273 4 Compound 105 10 272 106 11 270 270 5 Compound 158 10 253 152 15 255 106 11 253 6 No value could be obtained because of Compound 5 poor solubility in acetonitrile
[0363] The triphenylene derivative series 100, which are exemplified as Compounds 1 to 6, exhibit many advantageous luminescent properties (as demonstrated by the data in Tables 1 and 2, and
Large Stokes Shift
[0364] Compounds 1 to 6 exhibit large Stokes shifts in comparison with many commercially available dyes, e.g. the Alexa Fluor series (J Histochem Cytochem. Vol. 51(12): 1699-1712, 2003). It is believed that the Stokes shifts of Compounds 1 to 6 (Compound 6 in particular) are some of the largest Stokes shifts observed for known luminescent organic compounds.
[0365] Additionally, the advantageous luminescent properties such as the Stokes shift may be altered or tuned by variation of the R group within the triphenylene derivative series 100.
[0366] For example, as shown in Table 1 and
[0367] It should be noted that by Stokes shift, we also mean a pseudo Stokes shift. The IUPAC definition of the Stokes shift requires that the difference in the band maxima of the absorption and luminescence arise from the same electronic transition. However, it is widely referred to in the literature in general terms to mean the difference in excitation and emission wavelengths, regardless of electronic transition.
[0368] Without wishing to be bound by theory, we believe that the triphenylene derivative series 100 of the present invention are push-pull twisted internal charge transfer systems, wherein the triphenylene moiety when substituted with five electron-donating alkoxy groups (shown in
[0369] Emission across the entire Visible Spectrum, which varies with R group structure Advantageously, the emission spectra of Compounds 1 to 6 span a large portion of the visible spectrum. The R group need not be limited to those disclosed, and may be any alkyl or aryl group. In particular, variation of the R group with, for example, a different aromatic hydrocarbon group has been shown to result in a shift in the emission spectra. The shift in emission, and consequently the resulting visible colour of a specific triphenylene derivative, within the triphenylene derivative series 100, may be predicted with a good level of certainty for variation of the R group. Advantageously, this provides a huge number of analogues, for example wherein R is an aryl group, so that the emission is a colour within the visible spectrum, and this visible colour may be tuned by slight structural alteration to the R group of the triphenylene derivative series 100 of the present invention.
High Brightness
[0370] Compounds 1 to 6 exhibit very large molar extinction coefficients (E) of over 100,000 M.sup.1 cm.sup.1. This is comparable to commercially available dyes, for example, the Alexa Fluor series, e.g. Alexa Fluor 635 has a molar extinction coefficient of 140,000 M.sup.1 cm.sup.1.
[0371] Compounds 1 to 6 also advantageously exhibit high quantum yields and high brightness values. The quantum yield in this case is defined as the ratio of the number of photons emitted to the number of photons absorbed.
[0372] Consequently, the Compounds 1 to 6 exhibit high brightness values, the brightness being defined as the product of the molar extinction coefficient and fluorescence quantum yield.
[0373] Additionally, it has surprisingly been found that Compound 22 has a quantum yield of 93%.
Photoemission in the Solid State
[0374] Referring now to
[0375] Referring also to Table 3, there is shown a comparison of the photoemission of the Compounds 2 to 6 in the solid state and in ethyl acetate, and the difference between these values .
TABLE-US-00003 TABLE 3 Photoemission data for Compounds 2 to 6 Com- Com- Com- Com- Com- pound 2 pound 3 pound 4 pound 5 pound 6 Emission Emission Emission Emission Emission Max (nm) Max (nm) Max (nm) Max (nm) Max (nm) Ethyl 467 508 492 537 594 acetate Solid 467 520 509 533 575 state 0 +12 +17 7 19
[0376] Advantageously, the photoemission does not substantially change when Compounds 2 to 6 are dissolved in ethyl acetate in comparison to in the solid state. This demonstrates predictability and stability of photo-emissive behaviour.
Liquid Crystal Behaviour
[0377] Referring to Table 4 there is shown the DSC (Differential scanning calorimetry) thermal analysis for Compounds 1 to 6.
TABLE-US-00004 TABLE 4 DSC properties of Compounds 1 to 6 Compound Heating ( C.) Cooling ( C.) Phase Cr-X X-Col.sub.h Col.sub.h-I I-Col.sub.h Col.sub.h-Cr Compound 1 95 99 141 137 59 Compound 2 103 110 189 185 78 Compound 3 86 96 168 161 43 Compound 4 88 96 197 196 152* Compound 5 162 185 151 83 Compound 6.sup. 172 182 151 134 Cr-Col.sub.x Col.sub.x-I I-Col.sub.x Col.sub.x-Cr .sup.Compound 6 phase changes displayed in bold underneath the temperature
[0378] There is shown the phase transition for each of the Compounds 1 to 6, wherein Cr means crystalline, X means an unknown endothermic event, Col.sub.h means hexagonal columnar phase, and Col.sub.x means unknown liquid crystalline state. This shows that Compounds 1 to 6 are mesogenic, i.e. have liquid crystallinity.
[0379] Referring also to
[0380] The crystalline phase, the unknown solid phase, the columnar hexagonal phase, and the unknown liquid crystal phase are shown.
Photoconductivity
[0381] Referring to Table 5 there is shown the values for the average conductivity and the average photoconductivity of Compounds 1 to 6, when irradiated at 350 nm at room temperature. The molar absorptivity constant (E.sub.350 nm) at 350 nm in ethyl acetate is also provided. The conductivity and photoconductivity were also recorded for compound 403 shown in
TABLE-US-00005 TABLE 5 Conductivity and photoconductivity for Compounds 1 to 6 Average Average (.sub.350 nm) 10.sup.3 in ethyl Conductivity Photoconductivity Compound acetate M.sup.1 cm.sup.1 (S cm.sup.1) (S cm.sup.1) Reference 403 3.6 2.4 10.sup.13 1.98 10.sup.11 Compound 1 6.4 5.3 10.sup.13 .sup.2.0 10.sup.10 Compound 2 19 6.6 10.sup.12 3.1 10.sup.9 Compound 3 26 4.1 10.sup.12 6.9 10.sup.9 Compound 4 16 1.7 10.sup.11 2.3 10.sup.9 Compound 5 19 9.3 10.sup.12 1.5 10.sup.9 Compound 6 11 2.0 10.sup.12 .sup.1.1 10.sup.10
[0382] Advantageously, Compounds 1 to 6 show an increase in conductivity, i.e. the photoconductivity values, upon light irradiation. The conductivity and the photoconductivity is much higher for the triphenylene derivatives comprising an oxazole moiety, when compared to reference compound 403, which does not comprise an oxazole moiety. More advantageously, the photoconductivity increases significantly when the R group is a polycyclic aromatic hydrocarbon, i.e. for Compound 2, wherein R=Ph, and for Compounds 3 and 4, wherein R=naphthalene.
[0383] Referring also to
[0384] Surprisingly, Compound 3 displays improved conductivity, and photoconductivity, when the oxazole moiety is introduced. This is in comparison with the conductivity and photoconductivity of reference compound 403, which does not comprise an oxazole moiety substituted with an R group, as is characteristic of the triphenylene derivative series 100 of the present invention.
[0385] It has also been shown that compounds within the triphenylene derivative series 100 of the present invention do not undergo any appreciable photobleaching. The aforementioned properties make the triphenylene derivatives of the present invention highly suitable for use in solar cells.
[0386] Referring now to
[0387] The graph 1201 shows the electrical conductivity measurements for Compound 22 at different temperatures. Electrical conductivity measurements were recorded for Compound 22 in the presence and absence of irradiating UV light at 350 nm, and after treatment with HCl in the presence and absence of irradiating UV light at 350 nm.
[0388] The graph 1202 shows the electrical conductivity measurements for Compound 22 at different pH values. The electrical conductivity was measured for Compound 22: (i) untreated; (ii) after a first treatment with HCl; (iii) after 20 hours; (iv) after a second treatment with HCl; (v) and after treatment with NaOH.
[0389] The graph 1203 shows the electrical conductivity measurements for Compound 22 at different pH values. The electrical conductivity was measured for Compound 22: (i) untreated; (ii) after a first treatment with NaOH; (iii) after 20 hours; (iv) after treatment with HCl; (v) after a second treatment with NaOH.
[0390] Referring now to
[0391] (ii) untreated in the presence of UV light at 350 nm; (iii) after treatment with NaOH (2M for 15 minutes); (iv) after treatment with NaOH (2M for 15 minutes) in the presence of UV light at 350 nm.
[0392] Referring now to
Application of Triphenylene Derivative Series 100 in Electroluminescent Devices
[0393] The triphenylene derivatives of the present invention may also be used in a functional layer of an OLED (Organic Light Emitting Diode). It has been shown that the triphenylene derivatives of the present invention may exhibit excellent emitting, charge transporting, and/or charge blocking abilities.
[0394] Referring now to
[0395] Each layer described above may comprise any suitable material known to those skilled in the art, and may comprise more than one type of material or layer. For example, the substrate 1501 may comprise glass, quartz, polymers, and so on. The thickness is not critical and may be, for example, between 25 to 1000 microns depending on the application of the device. The anode 1502 may comprise any electrically conductive material, e.g. metal, or a conductive metal oxide such as ITO (indium tin oxide). The hole transport layer 1503 may comprise, for example, 1,4-bis[(1-naphthyphenyl)-amino]biphenyl (NPD). The emissive layer 1505 may comprise aluminium tris(8-hydroxyquinoline). The hole blocking layer 1506 may comprise 2,9-dimethyl-4,7-dipphenyl-1,10-phenanthroline (bathocuproine, BCP). The electron transport layer 1507 may comprise, for example, metal chelates such as, for example, aluminium tris(8-hydroxyquinoline). The cathode 1508 may comprise any metal, for example, aluminium, lithium, magnesium, and/or calcium.
[0396] The emissive layer 1505 comprises the triphenylene derivatives of the present invention, e.g. the triphenylene derivative series 100.
[0397] An OLED 1500 may be fabricated in the following manner: [0398] The anode 1502 is patterned upon the clean substrate 1501. [0399] The substrate 1501, which is patterned with the anode 1502, is treated with oxygen for 1 to 5 minutes. [0400] The substrate 1501, which is patterned with the anode 1502, is placed in a thermal evaporator and the pressure is reduced to below 610.sup.6 torr. [0401] The hole transport layer 1503, the electron blocking layer 1504, the emissive layer 1505, the hole blocking layer 1506, the electron transport layer 1507, and the cathode 1508 are successively formed in the listed order by thermal evaporation.
[0402] It will be appreciated by those skilled in the art that several variations to the aforementioned embodiments are envisaged without departing from the scope of the invention. For example, the R group of the triphenylene derivative series 100 and Precursors 1 and 2 need not be restricted to C.sub.5H.sub.11, and may be any stable alkyl or aryl group capable of alkylating the phenol moiety of the triphenylene moiety.
[0403] Advantageously, the triphenylene derivative series 100 of the present invention may be further functionalised, for example, by derivatisation of functional groups within the R group. This provides the possibility of using the triphenylene derivative of the present invention as biotags or probes, for example.
[0404] It will also be appreciated by those skilled in the art that any number of combinations of the aforementioned features and/or those shown in the appended drawings provide clear advantages over the prior art and are therefore within the scope of the invention described herein.